Real-world evidence for postmenopausal women with HR+, HER2- advanced breast cancer (aBC) treated with alpelisib (ALP): RIBANNA study protocol update

  • Autoren: Marcus Schmidt, Cosima Brucker, Thomas Decker, Jörg Falbrede, Peter Fasching, Helmut Forstbauer, Thomas Göhler , Oliver Hoffmann , Christian Jackisch , Jan Janssen , Andreas Köhler , Kerstin Lüdtcke-Heckenkamp, Diana Lüftner , Frederick Marmé , Arnd Nusch , Toralf Reimer , Christian Roos, Rudolf Weide  and Achim Wöckel
  • Institution: Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz; Departement of Gynecology and Obstetrics, Nuernberg General Hospital, Paracelsus Medical University; Oncology Ravensburg; Department of Obstetrics and Gynecology, Lukaskrankenhaus Neuss; Department of Obstetrics and Gynecology, University Hospital Erlangen; Department of Internal Medicine, Practice Network Hematology and Internal Oncology Troisdorf; Onkozentrum Dresden/Freiberg; Universitätsklinikum Essen;  Department of Obstetrics and Gynecology , Sana Klinikum Offenbach; Medizinische Studiengesellschaft Nord-West-GmbH, Westerstede; Gemeinschaftspraxis Dres. Köhler, Fuchs, Langen, Germany; Zentrum für Hämato-und Onkologie d. Niels-Stensen-Kliniken, Georgsmarienhütte; Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital Berlin; Med. Fakultät Mannheim der Univeersität Heidelberg; Pracitice for Hematology and Medical Oncology Velbert; University Hospital Rostock; Novartis Pharma GmbH, Nürnberg; Institute for Health Services Research in Oncology, Koblenz; Department of Obstetrics and Gynocology , University Hospital Würzburg
  • SABCS 2020 (Abstract)